Why Choose Us?
The novel nature of gene therapy candidates and the disease areas they are typically developed for means that much of the “traditional” medical affairs handbook is currently being re-written in order to effectively navigate much of the unique challenges that are associated with this field.
Much of the medical affairs work that is undertaken in the gene therapy field can fall quite accurately within the analogy of “Building the plane as you fly it”. The inaugural Gene Therapy Medical Affairs Summit will for the first time unite medical affairs, market access and HEOR leaders from the gene therapy space to share case studies and discuss what can be done to overcome the field’s greatest challenges.
Attend this virtual meeting to hear 20+ case studies from biotech and pharma medical affairs experts at the forefront of the gene therapy field. Explore themes including launch readiness, market access, medical affairs in clinical development, medical science communication, education and more. Learn how these leaders are transforming traditional medical affairs to launch the next generation of breakthrough gene therapy products.
So, I hear you ask, how will this meeting help my medical affairs team?
Built specifically for gene therapy medical affairs, market access and HEOR professionals, this digital meeting will unite the field’s experts to tackle your biggest medical affairs roadblocks, optimize your market access strategies, and explore what it takes for a successful launch!
Hear from the likes of Novartis Gene Therapy, Pfizer, Orchard Therapeutics, BlueBird Bio & GSK across 3 days of in-depth online case studies, interactive panel discussions, dedicated Q&A time, and highly appraised virtual networking opportunities to meet and learn from the leaders of this pioneering field.